UBS Oncology Impact Fund L.P. Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for UBS Oncology Impact Fund L.P..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of UBS Oncology Impact Fund L.P.. UBS Oncology Impact Fund L.P. is a 10% Owner in Oncorus, Inc. ($ONCR) and a 10% Owner in Harpoon Therapeutics, Inc. ($HARP) and a 10% Owner in TCR2 THERAPEUTICS INC. ($TCRR) and a 10% Owner in Cullinan Management, Inc. ($CGEM).
Address: C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE 02142 MA
Companies in which UBS Oncology Impact Fund L.P. is an Insider
Cullinan Oncology, Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of UBS Oncology Impact Fund L.P.: 10% Owner
Holdings: 1,136,525 shares
Latest Transaction: Jan 14 2021
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Harpoon Therapeutics, Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of UBS Oncology Impact Fund L.P.: 10% Owner
Holdings: 1,525,165 shares
Latest Transaction: Feb 14 2019
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Oncorus, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of UBS Oncology Impact Fund L.P.: 10% Owner
Holdings: 1,525,348 shares
Latest Transaction: Oct 08 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
TCR2 THERAPEUTICS INC.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of UBS Oncology Impact Fund L.P.: 10% Owner
Holdings: 2,421,775 shares
Latest Transaction: Feb 21 2019
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of UBS Oncology Impact Fund L.P.
Sentiment: All, CGEM, HARP, ONCR, TCRR
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 14 2021 | CGEM | Cullinan Managemen ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 649,030 | 0 | 0 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 2,276,692 | 0 | 0 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 3,551,640 | 0 | 0 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,136,525 | 0 | 0 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | P | 21.00 | 300,000 | 6,300,000 | 7,913,887 | 7.6 M to 7.9 M (+3.94 %) |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 649,030 | 0 | 7,613,887 | 7 M to 7.6 M (+9.32 %) |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 2,276,692 | 0 | 6,964,857 | 4.7 M to 7 M (+48.56 %) |
View all UBS Oncology Impact Fund L.P. insider transactions.